Standout Papers

Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients Wit... 2003 2026 2010 2018 2.3k
  1. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer (2008)
    Rafael G. Amado, Michael Wolf et al. Journal of Clinical Oncology
  2. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer (2003)
    Mark G. Kris, Ronald B. Natale et al. JAMA
  3. A well-conditioned estimator for large-dimensional covariance matrices (2003)
    Olivier Ledoit, Michael Wolf Journal of Multivariate Analysis
  4. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer (2007)
    Eric Van Cutsem, Marc Peeters et al. Journal of Clinical Oncology
  5. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 (2004)
    Giuseppe Giaccone, Roy S. Herbst et al. Journal of Clinical Oncology
  6. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 (2004)
    Roy S. Herbst, Giuseppe Giaccone et al. Journal of Clinical Oncology
  7. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study (2010)
    Jean‐Yves Douillard, Salvatore Siena et al. Journal of Clinical Oncology
  8. Improved estimation of the covariance matrix of stock returns with an application to portfolio selection (2003)
    Olivier Ledoit, Michael Wolf Journal of Empirical Finance
  9. Robust performance hypothesis testing with the Sharpe ratio (2008)
    Olivier Ledoit, Michael Wolf Journal of Empirical Finance

Immediate Impact

10 by Nobel laureates 17 from Science/Nature 135 standout
Sub-graph 1 of 13

Citing Papers

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
2023 Standout
Cryo-EM structure of a type IV secretion system
2022 StandoutNatureNobel
6 intermediate papers

Works of Michael Wolf being referenced

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Honey, I Shrunk the Sample Covariance Matrix
2003
and 1 more

Author Peers

Author Last Decade Papers Cites
Michael Wolf 2011 9350 3327 6667 181 19.2k
Peter A. Hall 3402 5649 3993 1821 333 36.0k
Ross L. Prentice 10114 6508 566 2705 380 41.6k
John D. Kalbfleisch 7988 1564 573 1478 142 23.3k
Donald A. Berry 3304 14358 160 3891 366 30.7k
Jeremy M. G. Taylor 4334 3892 173 4128 393 21.2k
Jun S. Liu 2880 3917 356 3673 451 41.2k
D. R. Cox 6147 988 1016 1002 120 20.7k
Mike West 2887 1423 1002 559 137 13.5k
Dongsheng Tu 1151 15262 132 8491 305 24.8k
David Peel 1864 833 2365 719 448 19.9k

All Works

Loading papers...

Rankless by CCL
2026